You are here

Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43EY034770-01
Agency Tracking Number: R43EY034770
Amount: $345,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NEI
Solicitation Number: PA21-259
Timeline
Solicitation Year: 2021
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-09-30
Award End Date (Contract End Date): 2024-08-31
Small Business Information
391 Chipeta Way Ste I
Salt Lake City, UT 84108-1264
United States
DUNS: 827576781
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 SARAH MOLOKHIA
 (385) 229-4491
 sarahmolokhia@hotmail.com
Business Contact
 GERALD SIMMONS
Phone: (385) 229-4491
Email: simmons45@gmail.com
Research Institution
N/A
Abstract

Project Summary
Pediatric myopia, also known as nearsightedness, is an eye condition in which one is unable to bring distant
objects into proper focus. It is the leading cause of vision impairment in the world. The estimated economic
impact of uncorrected refractive error is estimated to be a loss of $202 billion of global gross domestic product.
The prevalence of myopia and high myopia are increasing globally at an alarming rate, with significant increases
in the risks for vision impairment from pathologic conditions associated with high myopia, including retinal
damage, cataract and glaucoma. In 2000, the prevalence of myopia did not exceed 50% in any of the regions
but, by 2050, the prevalence will be ≥ 50% in 57% of the countries, if current trends continue.
We propose a novel topical eyedrop, IVMED-85, for treating myopia. It is a first in class medication that
upregulates lysyl oxidase to pharmacologically induce scleral and corneal crosslinking and stiffening.
Our central hypothesis is that the topical copper eyedrop treatment may enable a non-invasive, simple to use,
and relatively cost-effective treatment for myopia by pharmacologically inducing scleral and corneal collagen
crosslinking.
We provide the first evidence that our proprietary IVMED-85 eyedrops induce biochemical crosslinking and
biomechanical stiffening in cornea and sclera and reduced refraction and vitreous depth in guinea pig myopic
model (Preliminary results). In this project, we will test safety of IVMED-85 in rabbits (Aim 1) and further elucidate
efficacy and duration of effect after cessation in tree shrews, a para-primate model. Our plan is to achieve the
feasibility results of safety and efficacy from this proposed Phase 1 project to plan for a Phase 2 SBIR assessing
optimal duration in primates and GLP toxicology.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government